Related Experiment Video
Updated: Feb 3, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Pharmacotherapeutic management of gout in patients with cardiac disease
1a Department of Family Medicine , School of Medicine, International Medical University , Seremban , Negeri Sembilan Darul Khusus , Malaysia.
Insights
Hyperuricemia increases coronary artery disease (CAD) risk. While gout treatments exist, some, like NSAIDs, pose cardiac risks and should be avoided in CAD patients.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Hyperuricemia is an independent risk factor for coronary artery disease (CAD).
- Treatments for gout flares exist, but some carry cardiovascular risks.
Purpose of the Study:
- To review the cardiac safety of traditional and novel gout medications.
- To assess medication choices for gout patients with underlying CAD.
Main Methods:
- Review of current international guidelines on gout management.
- Analysis of cardiac safety profiles for various anti-gout medications.
Main Results:
- Non-steroidal anti-inflammatory drugs (NSAIDs) increase cardiac risk and should be avoided in CAD patients.
- Interleukin-1 inhibitors are presented as safe alternatives for cardiac patients with gout.
Conclusions:
- Further research is needed to determine if treating hyperuricemia reduces CAD risk.
- The cardiac safety of pegloticase in CAD patients requires further investigation.
Introduction:
Hyperuricemia has been identified as an independent risk factor for coronary artery disease (CAD). Uric acid lowering therapy could potentially lower the risk of CAD. Conventional treatments have been effective in treating acute gout flares in most patients, but certain options, like NSAIDs could increase the risk of CAD.
Areas Covered:
This review covers the aspect of cardiac safety with traditional and new medications used in treating both acute flares and chronic gout according to the most recent international guidelines.
Expert Opinion:
All NSAIDs, not just selective Cox 2 inhibitors, have associated with them different degrees of cardiac risk; therefore, NSAIDs should be avoided when treating patients with underlying CAD. Interleukin-1 inhibitors appear to be safe alternatives for treating cardiac patients who are contraindicated to conventional treatment. Presently, there is a paucity of evidence concerning whether treatment of hyperuricemia could lower the risk of CAD and this must be explored further. It is also important to explore the cardiac safety of plegloticase to better ascertain its safety in CAD patients.
More Related Videos
06:43Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
Published on: November 21, 2017
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
Related Concept Videos
Cardiac Catheterization IV: Nursing Management
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Rheumatic Heart Disease III: Medical Management
Peripheral Artery Disease V: Postoperative Nursing Management